CALML6 Controls TAK1 Ubiquitination and Confers Protection against Acute Inflammation

J Immunol. 2020 Jun 1;204(11):3008-3018. doi: 10.4049/jimmunol.1901042. Epub 2020 Apr 17.

Abstract

Proper regulation of innate immune response is important for individual health. The NF-κB signaling pathway plays crucial roles in innate immunity and inflammation, and its aberrant activation is implicated in diverse diseases and disorders. In this study, we report that calmodulin-like 6 (CALML6), a member of the EF-hand protein family, is a negative regulator of the NF-κB signaling pathway. CALML6 attenuated TNF-stimulated phosphorylation of proteins downstream of TGF-β-activated kinase 1 (TAK1) and inhibited TAK1-induced NF-κB activation. Further studies showed that CALML6 interacted with TAK1 and recruited the deubiquitylating enzyme cylindromatosis to repress the K63-linked polyubiquitination of TAK1. CALML6 transgenic mice had higher tolerances to lethal LPS treatment in vivo. These findings suggest that CALML6 is a negative regulator of the NF-κB signaling pathway, which is important for maintaining the balance of the innate immune response.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Calcium-Binding Proteins / genetics
  • Calcium-Binding Proteins / metabolism*
  • Calmodulin / genetics
  • Calmodulin / metabolism*
  • Disease Models, Animal
  • Homeostasis
  • Humans
  • Immunity, Innate
  • Inflammation / metabolism*
  • MAP Kinase Kinase Kinases / metabolism
  • Mice
  • Mice, Transgenic
  • NF-kappa B / metabolism
  • Phosphorylation
  • Protein Binding
  • Sepsis / metabolism*
  • Signal Transduction
  • Transforming Growth Factor beta / metabolism
  • Tumor Necrosis Factor-alpha / metabolism
  • Ubiquitination

Substances

  • CALML6 protein, human
  • Calcium-Binding Proteins
  • Calmodulin
  • NF-kappa B
  • Transforming Growth Factor beta
  • Tumor Necrosis Factor-alpha
  • MAP Kinase Kinase Kinases
  • MAP kinase kinase kinase 7